Qualified individuals must be male or female, aged 40 or older with established cardiovascular (CV) disease, defined as any of the following:

- Previous myocardial infarction

- Previous ischemic stroke

- Symptomatic peripheral arterial disease (PAD)

At the Screening Visit, participants must also be on a stable and well-tolerated lipid-lowering regimen.

Participants will receive an investigational medication (active study drug) or placebo, via injection. Study medication and study-related assessments will be provided at no cost. Reimbursement for study-related expenses may be provided.

Study participation will last about 3-6 years depending on when participants enter the study. The number of visits to the study centre will vary (4 to 7 times in the first year, and then twice a year thereafter).

Call the study centre near you, or register now.